Sign Out
DOVATO is contraindicated in patients with known hypersensitivity to dolutegravir or lamivudine, or to any of the excipients.
DOVATO must not be administered concurrently with medicinal products with narrow therapeutic windows, that are substrates of organic cation transporter 2 (OCT2), including but not limited to dofetilide, pilsicainide or fampridine (also known as dalfampridine; see Interactions).
Continue with Google